BFRI Share Price Performance
US$0.81
-0.23 (-21.89%)
87.3% undervalued intrinsic discount
US$6.38
Fair Value
Price US$0.81
AnalystConsensusTarget US$6.38
AnalystLowTarget US$3.00
AnalystHighTarget US$10.00
Fair ValueUS$6.50
Share Pricen/a
Biofrontera Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
BFRI Community Narratives
AN
Fair Value US$6.5 87.5% undervalued intrinsic discount
Label Expansion And New Trials Will Fuel US Dermatology Demand
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$3 72.9% undervalued intrinsic discount
Regulatory And Litigation Risks Will Constrain Growth But Enable Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$10 91.9% undervalued intrinsic discount
Ameluz Expansion Will Harness Secular Trends In Dermatology
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Ameluz Expansion Will Harness Secular Trends In Dermatology
Key Takeaways Full US manufacturing control, improved reimbursement, and label expansion could drive a step-change in market share, margins, and top-line growth beyond current expectations. Data-driven salesforce expansion, clinician preference shifts, and global market opportunities position the company for outsized, multi-region scaling and profit growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$10
91.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
19.97% p.a.
Profit Margin
27.18%
Future PE
8.61x
Price in 2028
US$6.75
Label Expansion And New Trials Will Fuel US Dermatology Demand
Key Takeaways Expansion of Ameluz indications, improved reimbursement, and patent extension are set to drive revenue growth and strengthen market position amid rising skin cancer rates. Reduced costs due to lower royalties and focus on new dermatological indications are expected to improve margins and enable future product launches.Read more
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$6.5
87.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
21.29% p.a.
Profit Margin
30.7%
Future PE
4.79x
Price in 2028
US$4.39
Regulatory And Litigation Risks Will Constrain Growth But Enable Recovery
Key Takeaways Heavy reliance on a single product and exposure to litigation and patent costs threaten earnings and margins despite operational improvements and potential for higher profitability. Growth prospects are challenged by regulatory and pricing pressures, uncertain R&D outcomes, and vulnerability to sector consolidation due to its smaller market presence.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
72.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
19.81% p.a.
Profit Margin
27.01%
Future PE
2.61x
Price in 2028
US$2.03
Trending Discussion
Recently Updated Narratives
AN
Regulatory And Litigation Risks Will Constrain Growth But Enable Recovery
Fair Value: US$3 72.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Ameluz Expansion Will Harness Secular Trends In Dermatology
Fair Value: US$10 91.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Label Expansion And New Trials Will Fuel US Dermatology Demand
Fair Value: US$6.5 87.5% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Biofrontera Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.51
- 64.41%
- -47.28%
- -172.9%
About BFRI
- Founded
- 2015
- Employees
- 93
- CEO
- WebsiteView website
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
